Lung disease is the main cause of morbidity and mortality in cystic fibrosis (CF) 
INTRODUCTION
The lack or reduced presence at cell surfaces of fully functional cystic fibrosis conductance regulator (CFTR) in people with cystic fibrosis (CF) results in a build-up of dense, dehydrated mucus that promotes infection and thus, chronic inflammation [1] . Additionally, CF has been labeled a mucosal immunodeficiency syndrome because of the direct proinflammatory effects of CFTR dysfunction on the dysregulation of epithelial innate immunity and airway leukocytes [2] . As such, the pathophysiology of the CF lung is highly complex, involving numerous interactions between multiple human cell types and a diverse microbiota [3] [4] [5] , as well as the inherent impairment of several cell types.
Proteomic studies of the CF airways have investigated protein abundance in epithelial cells cultured in vitro or obtained from animal models or clinical samples [6] [7] [8] [9] [10] [11] [12] [13] . Furthermore, several studies have assessed the extracellular proteomes of CF sputum, bronchoalveolar lavage fluid (BALF) and bronchial epithelial cell secretions [14] [15] [16] [17] [18] [19] . The main observations of these studies are summarised in the online supplement (Table E1) . Although these studies have all contributed to our understanding of CF, investigations of single cell types, in vitro cultures and animal models have limited relevance to in situ CF lung pathogenesis. To date, the contribution of the global proteome of all cell types in the proportions occurring naturally in CF sputum has not been investigated. We hypothesized that proteins detected in sputum cells can have a detrimental effect on CF lung health, both through their effect on cell functioning and activities, and through their release into extracellular sputum fluid by means of active secretion or cell death.
We employed quantitative comparative proteomics to characterise the global activity and protein composition of cells in CF sputum from adults chronically infected with P. 4 aeruginosa to provide insight into potential mechanisms of lung disease and to identify candidate biomarkers associated with poor lung function in this population.
By employing these methods we were able to identify, in clinical samples, novel cellular proteins and activities likely to be clinically relevant as mechanisms for tissue damage and disease progression.
METHODS

Study participants
Twelve adults with CF, aged 26.8 ± 5.98 (mean ± SD; range [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] were recruited at Belfast City Hospital on admission for treatment with intravenous antibiotics for an acute pulmonary exacerbation as defined by Fuchs et al. [21] . Seven were male and five female. All were chronically infected with P. aeruginosa. Their characteristics and treatment regimens are recorded in Table 1 and Table E2 (online supplement), respectively. Three induced sputum samples were collected from each CF participant at times of differing clinical status -untreated pulmonary exacerbation, within 24h of completing intravenous antibiotic treatment of exacerbation and 4-15 weeks after completion of treatment. Lung function was measured as FEV1 % predicted prior to each sputum collection. Twelve non-smoking, healthy control participants, aged 29.6 ± 4.27 (mean ± SD; range [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] 
Sample preparation
For each sputum sample the cell population was harvested from mucus plugs, washed and proteins extracted. Briefly, approximately 1g of mucus plug was homogenised thoroughly with 9 ml sterile phosphate buffered saline and the cells pelleted by centrifugation. Following two further wash steps and cell straining to remove clumps, the cells were pelleted to remove all traces of supernatant. The pellet was then homogenised thoroughly in lysis buffer and subjected to repeated freeze-thaw and water bath sonication to ensure cell lysis. Insoluble debris was removed by centrifugation. All work was carried out at 4⁰C and in the presence of a protease inhibitor cocktail. Full method details are given in the online supplement.
Proteomic methods
Protein digestion and iTRAQ labelling were performed as described previously {{904 Scuoppo,C. 2012}} and details are recorded in the online data supplement. Protein digestion with trypsin and labelling with 8plex iTRAQ Reagents (AB Sciex) were performed as described previously [22] . Six test samples and a reference sample were mixed for simultaneous analysis by 2D liquid chromatography MudPIT on line with an LTQ Orbitrap Velos (Thermo Electron) as described previously [22] . Further details of the methods employed for MudPIT are recorded in the online data supplement.
Protein identification
Peaklists were generated by Mascot Distiller and protein identification was performed by the Mascot search engine against the UniProt database plus NCBI 
RESULTS
Core signature proteome in CF cohort
In accordance with inclusion criteria, the CF cohort comprised adults with CF who were chronically infected with P. aeruginosa. The cohort's variation in % FEV1
predicted ( proteins were detected in all samples belonging to only one cohort suggesting low abundance or absence in the other cohort, although differential abundance between the two cohorts cannot be proven statistically. Twenty-one proteins were detected only in the CF cohort and 17 proteins were detected only in the control cohort. Table   9 E3 in the online data supplement records all proteins detected in all the samples belonging to at least one cohort.
The heatmap in Figure 1 , which clusters individual sputum samples according to relative abundance levels (sample:reference) of consistently detected proteins,
shows that CF and control samples largely cluster separately. The two exceptions, CF3.2 and CF4.2 (marked with an arrow in Figure 1 ), are CF samples collected just after completion of antibiotic treatment for a pulmonary exacerbation.
IPA Canonical Pathways in CF and control cohorts
The 136 proteins detected in all control samples and the 140 proteins detected in all CF samples were treated as consensus core proteomes for the two cohorts. 
IPA Bio Function analysis of the CF differential proteome
Comparison of relative abundance levels (sample:reference) between the two 
High abundance proteins in CF sputum cells
As high abundance proteins have greater potential for directly impacting the lung environment, we identified proteins that were consistently detected at high abundance per sample in the CF cohort and determined if their abundance levels per sample differed significantly from those of the control cohort. Six proteins were found to each comprise >1% of total human cellular protein per sample (% emPAI) in >80% of CF samples. Comparison of the % emPAIs for these proteins between CF and control cohorts detected increased abundance of all six in CF (independent samples
Mann-Whitney U test, p<0.01). Their median±IQR % emPAIs are displayed in Figure   4 along with the corresponding data for the control cohort. The Human Protein Atlas [26] identifies all as being either highly or moderately expressed in bone marrow Figure E1 (online data supplement) shows that total protein yield (mg per g sputum)
Longitudinal analysis of antibiotic treatment of CF exacerbation
consistently decreased for each CF participant following antibiotic treatment of exacerbation and that follow-up samples collected during clinical stability more closely resembled pre-treatment samples with respect to yield. Individual proteins identified as correlating negatively with FEV1 % predicted (n=17) or consistently at high abundance in CF (n=6) were analysed to compare the relative abundance (sample:reference) of matched CF pre-treatment and <24h post-treatment samples.
As shown in Table 2 , paired samples T-tests (including Benjamini-Hochberg multiple comparisons adjustment of false discovery rate adjustment to <0.05) identified 9
proteins with decreased abundance (p<0.05) following treatment of pulmonary exacerbation. Figure 1 shows that for 7 of the 12 individuals with CF, samples collected during clinical stability (labelled ".3") clustered more closely with the matched pre-treatment sample (".1") than the post-treatment sample (".2").
ELISA validation of candidate biomarkers
As high abundance proteins ( Figure 4 ) have greater potential for directly impacting the lung environment, we chose to validate myeloperoxidase and lactotransferrin as candidate biomarkers. Quantification of our existing samples by commercial ELISA confirmed their consistently higher abundance in CF compared to healthy control sputum cells (p<0.05, Mann Whitney U test, Figure E2 in the online supplement).
Additionally, this demonstrated that commercial ELISAs are a practical method for follow-up validation of candidate biomarkers in a larger independent cohort.
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DISCUSSION
In order to further elucidate the mechanisms of CF-associated tissue damage in adults with chronic respiratory P. aeruginosa infection, this study has for the first time specifically investigated the global proteome and functional activity of the combined population of cells present in CF sputum. As such, it uniquely studies the protein abundance of cells in vivo, thereby taking into account both their natural frequency in the sputum cell population and the effects of intercellular interactions. Thus, it delivers a high degree of clinical relevance to our findings. Moreover, to accurately characterise a consistent CF phenotype for adults chronically infected with P.
aeruginosa and avoid bias due to patient individuality, we considered only those proteins detected in all samples within the CF and healthy control cohorts. Thus, our study is more stringent than previously published proteomic studies that either included proteins detected at high frequency in at least one sample [18] or used pooled samples [14] [15] [16] .
In agreement with previous investigations of CF sputum or BAL [14, 15, 17, 18] , we found the CF proteome to be largely distinct from that of the control cohort. IPA predicted that Canonical Pathways which affect or involve actin cytoskeleton rearrangement directed by the Rho family small GTPases, including RhoA, Rac1 and Cdc42 were over-represented in the CF samples. Thus, our in vivo data confirms previous in vitro observations linking CFTR deficiency with increased RhoA expression [27, 28] . This may be significant for CF lung health as impaired efferocytosis (phagocytosis of apoptotic cells) [29] and reduced expression of iNOS [28] resulting from CFTR deficiency have been reported as mediated by RhoA upregulation.
Similarly to previous proteomics studies of cell-free CF sputum/BAL, GO and IPA Bio
Function analyses identified up-regulation of the immune and inflammatory response [14] [15] [16] [17] [18] . In particular, we found increased immune cell movement and activation, and generation of reactive oxygen species. These observations fit with existing knowledge about the CF phenotype which is typified by chronic inflammation and neutrophilia. Interestingly, an IPA predicted network identified lipopolysaccharide as a likely trigger of inflammation. Cell death, growth and proliferation were also predicted as dysregulated in CF, in such a way that both death and proliferation of immune cells were decreased, while both were increased in non-immune cells.
These observations further support the growing understanding of the CF phenotype.
Tissue damage and cell death is rampant, while excessive proliferation of respiratory epithelial cells leading to squamous cell metaplasia and dysplasia is common in CF [30, 31] . Delayed neutrophil apoptosis and clearance is thought to contribute to chronic inflammation [2] and our study detected CF-associated differential abundance of matrix metalloproteinase 8, annexin I and nicotinamide phosphoribosyltransferase, which have been implicated in delayed apoptosis and clearing of inflammatory and immune cells in vitro [32] and in vivo [33, 34] .
Compositional breakdown analysis of sample proteomes found S100-A9, the histone H2B family, lactotransferrin, histone H4, cathepsin G and myeloperoxidase to be consistently present in high abundance in CF and to each be significantly more abundant in the CF cohort than the control cohort. Importantly, all six proteins are known constituents of neutrophil extracellular trap (NET) structures, the release of which by neutrophils exerts antimicrobial activity through the degradation of virulence factors, bacterial killing and antifungal activity [35] [36] [37] .
As our study focused on sputum cellular proteins we did not look specifically for NET structures, which are extracellular, and therefore do not know if they were present.
However, NETs have been found previously in the CF airways fluid and the abundance of free DNA that is characteristic of NETs correlated with obstructive lung function [38] . As well as killing microbes, NETs have been found to directly induce human alveolar epithelial and endothelial cell death, with the predominant cytotoxic effect being attributed to histones and myeloperoxidase [39] .
Individually, these six high abundance proteins may also have significance for CF lung pathology and several have previously been reported as up-regulated in CF sputum and/or BALF [14, 15, 18] . Importantly, differential abundance of myeloperoxidase in CF sputum fluid has been correlated with FEV1 % predicted [17] , and myeloperoxidase and calgranulin B have been identified in sputum fluid as CFassociated autoantigens [16] . Cathepsin G has been implicated in degradation of surfactant protein A, so reducing the innate pulmonary antimicrobial defence [40] , while S100-A9 has been shown to induce MUC5AC production in human bronchial epithelial cells cultured in vitro, suggesting a potential contribution to pathological mucin hyperproduction in vivo [41] . In a study investigating trauma-induced lung injury, Abrams et al. reported that histones induced NET formation and myeloperoxidase release in vitro, while histone infusion in mouse models resulted in lung structural damage and neutrophil congestion [42] . Additionally, extracellular histones H4 and H3.3 have been implicated in asthma-related inflammation and remodeling, and in chronic obstructive pulmonary disease (COPD), respectively [43, 44] . Consequently, our consistent detection of these proteins in such high abundance in the sputum cellular fraction identifies a potential risk to lung health, 18 either through their active secretion and NET formation or following passive release into the sputum fluid via cell death.
A number of proteins detected consistently in CF sputum correlated negatively with lung function measured as FEV1 % predicted. Their biological/clinical relevance and potential for causing injury are discussed more fully in the online supplement.
Longitudinal analysis of patient-matched CF samples showed differential abundances for 10 out of these 17 proteins in the CF cohort following intravenous antibiotic treatment of a pulmonary exacerbation. Interestingly, all the changes in abundance resulted in levels closer to those in the control cohort. Previously, Sloane et al [17] observed that for 4/13 adults with CF, their cell-free sputum proteome profiles moved closer to those of healthy controls following antibiotic treatment of an exacerbation. However, the latter observations were made by comparison of 2-D gel images rather than implicating and identifying particular proteins. We also found that, although sputum total protein yield decreased in the CF cohort by completion of antibiotic treatment, it had reverted to pre-treatment levels by the clinically stable follow-up time point. This suggests that proteomic changes associated with antibiotic treatment may be temporary.
Overall, the proteins detected as negatively correlating with FEV1 suggest that the degree of inflammation, neutrophil influx, protease activity and airway remodeling may all contribute to defining lung function. Alpha-1-antitrypsin and olfactomedin-4
were identified as independent factors negatively correlating with FEV1 although this does not demonstrate causation of harm. Acute inflammation-associated protein alpha-1-antitrypsin has previously been identified as a biomarker of pulmonary disease in CF which can be predictive of response to treatment and prognosis [45] .
As an inhibitor of neutrophil serine proteases, which contribute significantly to lung destruction in CF, its negative correlation with lung function might seem surprising.
However, previous studies observed that plasma deficiencies during inflammation were associated with less severe lung disease in CF [46] . No association between olfactomedin-4 and CF lung health has previously been reported. However, olfactomedin-4 has been shown to down-regulate proinflammatory responses to bacterial infection and reduce bacterial killing mediated by granule serine proteinases [47, 48] , which could have the potential to negatively affect lung health.
There are a number of limitations to our study. As is typical for untargeted exploratory proteomic studies, we used highly sensitive shotgun technologies to obtain quantitative, high proteome coverage analysis of sputum cells as a novel target. The trade-off for such in-depth analysis is a relatively low sample size. Given the sample numbers practicable, we maximised power by restricting the study to adults with CF chronically infected with P. aeruginosa, who experienced pulmonary exacerbation requiring hospitalization for treatment with intravenous antibiotics.
While CF sputum proteome responses to other microbial infections may vary, we considered this cohort most informative as 57% of the adult CF population is chronically infected with P. aeruginosa [49] . As this study investigated only adults the findings cannot be extended to children or individuals not chronically infected with P aeruginosa. Although proteins reported as potentially damaging were detected as consistently abundant or correlating negatively with lung function in our study, this is not proof of causation of lung injury. Additionally, the limited sample size requires that any potential significance as biomarkers either of lung function or disease severity warrants validation in a larger independent cohort. As an intial stage in this validation process we used commercial ELISAs to confirm findings in our existing cohort for myeloperoxidase and lactotransferrin. 
